Isthmus Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Isthmus Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,627	Closed	-$937K	–	201
2019 Q1	$937K	Buy	+14,627	New	+$258K	0.23%	90
2018 Q4	–	Sell	-312	Closed	-$7K	–	264
2018 Q3	$7K	Hold	312	–	–	﹤0.01%	255
2018 Q2	$8K	Hold	312	–	–	﹤0.01%	239
2018 Q1	$5K	Hold	312	–	–	﹤0.01%	250
2017 Q4	$6K	Hold	312	–	–	﹤0.01%	261
2017 Q3	$5K	Hold	312	–	–	﹤0.01%	283
2017 Q2	$10K	Hold	312	–	–	﹤0.01%	253
2017 Q1	$10K	Hold	312	–	–	﹤0.01%	259
2016 Q4	$11K	Hold	312	–	–	﹤0.01%	256
2016 Q3	$14K	Buy	+312	New	+$16.3K	﹤0.01%	231

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Isthmus Partners's TEVA Position: Q2 2019 in Review

Isthmus Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2019, closing a stake of 14,627 shares — an estimated $937K sold.

Isthmus Partners first reported a position in TEVA in Q3 2016 and held it in 10 quarters. The position peaked at $937K in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Isthmus Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2019 after selling out during the quarter.
Isthmus Partners sold 14,627 Teva Pharmaceutical Industries Limited shares in Q2 2019, an estimated $937K.
Isthmus Partners first reported a position in Teva Pharmaceutical Industries Limited in Q3 2016 and held it in 10 quarters.
Isthmus Partners's Teva Pharmaceutical Industries Limited position peaked at $937K in Q1 2019.
452 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2019.

Based on Isthmus Partners's 13F filing for Q2 2019, filed 9 Aug 2019.